Video Insights
Video Insights
Advertisement
Tycel Phillips, MDMantle Cell Lymphoma | June 21, 2024
The 15-month PFS was approximately 33% for patients who were BTK exposed and over 50% for patients who were BTK naïve.
View More
Eric Winer, MDAcute Myeloid Leukemia | June 21, 2024
Drs. Winer, Daver, and Abaza discuss the major breakthroughs in the treatment of acute myeloid leukemia.
Eric Winer, MDAcute Myeloid Leukemia | June 17, 2024
Drs. Winer, Abaza, and Daver discuss their own treatment strategies for patients with AML.
Ola Landgren, MD, PhDMyeloma | June 17, 2024
Ola Landgren, MD, PhD, discusses three studies on quadruplet therapy presented at the 2024 ASCO Annual Meeting.
Jorge Cortes, MDChronic Myeloid Leukemia | June 14, 2024
The rate of response was “significantly higher” with asciminib compared with tyrosine kinase inhibitors.
Melissa BadamoVideo Insights | June 12, 2024
Dr. El-Jawahri discusses exciting ASCO sessions, such as the plenary session that focused on telehealth and palliative care.
Advertisement
Mazyar Shadman, MD, MPHChronic Lymphocytic Leukemia | June 12, 2024
The study utilized three clinical trials to compare the efficacy of acalabrutinib, zanubrutinib, and ibrutinib for CLL.
Manali Kamdar, MDMeeting News | June 6, 2024
Manali Kamdar, MD, shared results from the pivotal phase III TRANSFORM study on lisocabtagene maraleucel in LBCL.
Chadi Nabhan, MD, MBA, FACPVideo Insights | June 7, 2024
Himachandana Atluri, MD, describes the experience and ins and outs of becoming a new fellow.
Melissa BadamoChronic Lymphocytic Leukemia | May 29, 2024
Liso-cel was approved in March 2024 by the FDA for patients with relapsed or refractory CLL.
Prithviraj Bose, MDMyelofibrosis | May 2, 2024
Prefibrotic myelofibrosis is the focus of “SOHO State of the Art Updates and Next Questions.”
Guillermo Garcia-Manero, MDAcute Myeloid Leukemia | May 2, 2024
Early detection and prevention are particularly important in leukemia, Dr. Garcia-Manero explained.
Geoff Chong, MDIndolent B-Cell Lymphoma | May 7, 2024
The ELM-2 trial studied odronextamab in patients with relapsed or refractory follicular lymphoma.
Donna Catamero, ANP-BC, OCN, CCRCMyeloma | May 21, 2024
Donna Catamero, ANP-BC, OCN, CCRC, discusses selinexor for myeloma, the BOSTON trial, and other recent advances in myeloma.
Michel Zwaan, MD, PhDAcute Lymphoblastic Leukemia | April 22, 2024
A phase II study presented at ASPHO 2024 evaluated revumenib in KMT2A-rearranged ALL and AML.
Simona Colla, PhDMyelodysplastic Syndromes | April 19, 2024
Dr. Colla describes her current research at MD Anderson, such as developing new therapeutic approaches to MDS.
Francesco Bertoni, MD, PhDAggressive B-Cell Lymphoma | April 30, 2024
Dr. Bertoni and colleagues characterized two small nucleolar RNAs that exert tumor suppressor activity in DLBCL cells.
Catherine Coombs, MDChronic Lymphocytic Leukemia | April 19, 2024
Catherine Coombs, MD, outlined some of her research into the solid tumor microenvironment, particularly in prostate cancer.
Magdi Elsallab, MD, PhDTransplantation & Cellular Therapy | April 17, 2024
In approximately 12,000 reports of adverse events, the researchers found 19 cases of T-cell malignancies after CAR-T.
Melissa BadamoMyelodysplastic Syndromes | April 16, 2024
The average rate of progression for CHIP to MDS or AML is about 1% per year, Dr. Patel explained.
Advertisement
Advertisement
Editorial Board